泰利福 2024年度报告

Financial Highlights From Continuing Operations(Dollars In Millions, Except Per Share Data) ¹A table reconciling adjusted earnings per share to the most directly comparable GAAP measure can be found at the end of thisAnnual Report. • Our “durable core” portfolio includes Teleflex products outside of the “high-growth” and “other” categories. Empowering the Futureof Healthcare At Teleflex, our purpose is to improve the health and quality of people’s lives.We work toward this goal by providing healthcare professionals with innovativemedical devices and technologies that can help to improve patient outcomes,reduce costs, and create efficiencies. We support our healthcare innovationsby offering in-depth clinical education programs and maintaining a best-in-classglobal supply chain. Our leadership team leverages these strengths to fulfillour corporate purpose while generating long-term durable growth for ourshareholders, employees, and business partners. Vision Strategy People Our vision is to be the mosttrusted partner in the globalhealthcare market to allof our constituents, includingvendors, suppliers, customers,and regulators. We seek to generate long-term durable growth bydriving revenues, expandingmargins and earnings,optimizing our productportfolio, and advancing ourcorporate social responsibilityand inclusivity initiatives. From our proven leadershipteam, to our 14,100 employeesaround the world, Teleflex ismade up of highly dedicatedindividuals who are committedto improving the health andquality of people’s lives. Teleflex has a strong and growing product portfolio that comprises many trusted names in medical technology,including Arrow™, Barrigel®, Deknatel™, LMA™, Pilling™, Rüsch™, QuikClot™, UroLift™, and Weck™. Dear Shareholders In 2024, we continued to execute our strategy to drive long-termdurable growth and to fuel progress across our business. As a result,we are well positioned to deliver value for our customers and thepatients they serve. 2024 Highlights: •We drove organic growth, increasing our R&Dto revenue ratio, and launching new productsinto high-growth markets. •We grew adjusted margins and increasedadjusted operating incomeby leveragingour diversified portfolio and global footprint. •We expanded our capital allocation strategy,introducing a share repurchase programto enhance long-term value creation. •We leveraged our M&A strength, integratingPalette Life Sciences and its innovative Barrigel®product into our business. Liam Kelly congratulates John Deren on his appointment to the role of Executive Vice Presidentand Chief Financial Officer of Teleflex, following the retirement of Thomas Powell, which willbe effective April 2, 2025. The force behind our progress is our team of 14,100employees around the world. Our people trulyunderstand the importance of the work we do, andthey demonstrate this by upholding quality in theirrespective roles every day. We would like to thankeach of them for their ongoing commitment to ourcorporate purpose of improving the health andquality of people’s lives. capital to shareholders through dividends.During the year, we augmented this programby authorizing a $500 million share repurchaseplan, including a $200 million accelerated sharerepurchase, which we launched in August 2024.We expect this new initiative to increaseshareholder returns, and to create additionallong-term value for our shareholders. Creating Shareholder Value Expanding Our Portfolio In 2024, we grew net cash provided by operatingactivities by 24.7% to $638.3 million. This provides astrong foundation to execute our existing capitalallocation strategy and to expand this strategy sowe can return additional capital to shareholders.Historically, our capital allocation activities haveincluded developing internal growth opportunities,investing in M&A, paying down debt, and returning Teleflex is a highly disciplined acquirer. We have aproven M&A process, along with a strong trackrecord for buying assets that are accretive to growth.Since 2018, we have made a series of strategic tuck-inacquisitions that have brought us differentiatedproducts and technologies in high-growth markets.These include our acquisitions of Essential Medical,Z-Medica, HPC Medical, Standard Bariatrics, and supported by our Core Values, which provide thefoundation for how we conduct ourselves in everybusiness function, in every part of the world, everyday. In 2024, we continued to advance each tenetof our CSR program, delivering on our commitmentsto ethics and governance, the environment, people,the community, and sustainable healthcare. Ourdiligence in these areas has been recognizedrepeatedly. In 2024, Teleflex earned Great Placeto Work commendations in Australia, China, India,and Malaysia, and we were named to the Forbeslist of Best Places to Work for Engineers. most recently, Palette Life Sciences, which wecompleted in late 2023. Palette Life Sciences broughtus Barrigel®, a Non-Animal Stabilized Hyalur